Week of October 12 to October 19, 2026
RT CHARM validates 3-week PMRT post-reconstruction; ESMO next week
Calendar note: The ESMO Congress 2026 runs October 23 to 27 in Madrid (per the official ESMO programme). The breast late-breaking slate lands next week, so this week is deliberately light on readouts: expect NATALEE 6-year OS, TALENT final neoadjuvant T-DXd data in HER2-low early disease, PANKU-Breast01, KEYNOTE-B49, FINER OS, postMONARCH OS (scheduled October 24 per a Lilly preview issued October 18), OptiTROP-Breast01 final OS, and the SWITCH ADC-sequencing platform trial. This edition covers the in-window journal literature, one FDA device clearance, and pipeline posture. ESMO 2026 Programme (PDF).
Practice-Relevant Clinical
Lead: RT CHARM (Alliance A221505), published online in JCO October 12
Hypofractionated postmastectomy radiation (42.56 Gy in 16 fractions over 3 weeks) was noninferior to conventional PMRT (50 Gy in 25 fractions over 5 weeks) in women with unilateral invasive breast cancer who planned breast reconstruction. The 24-month breast reconstruction complication rate was 12.3% (52 of 422) with hypofractionation versus 10.2% (41 of 403) with conventional PMRT, difference -2.1% (noninferiority P = .0001). Recurrences were 10 versus 8 with no significant difference. Grade 3 or higher acute nonreconstruction-related toxicity was 5.0% versus 7.7%. Within the follow-up window, 84% of patients completed reconstruction and 76% did so within 18 months of radiotherapy.
Implication: For patients undergoing reconstruction who need PMRT, a 3-week course can be offered without compromising reconstruction outcomes, saving 9 fractions of travel and toxicity exposure. This extends the hypofractionation standard into the reconstruction population, where practice has been more conservative. Sources: Poppe et al, J Clin Oncol (online October 12, 2026) and ASCO Post summary.
SLNB after neoadjuvant chemotherapy in locally advanced breast cancer (Barrio et al, JCO, online this week)
A prospective, multicenter, single-arm study of 145 patients with locally advanced breast cancer (clinical T4 and/or N2/N3; 44% inflammatory, 23% other T4, 12% N2, 21% N3) who became clinically node negative after neoadjuvant chemotherapy. All underwent SLNB with dual-tracer mapping followed by completion ALND.
- At least one sentinel node was identified in 74% (108 of 145); identification was better in advanced nodal disease (83 to 87%) than in T4 disease (67 to 73%).
- Among 87 patients with adequate mapping (3 or more SLNs, or 1 to 2 SLNs with retrieval of the clipped metastatic node), 46% had nodal pCR. Among the 47 with residual nodal disease, there was one false negative: FNR 2.1% (95% CI 0.1 to 12.7).
- Adequacy mattered: among 21 patients with 1 to 2 SLNs retrieved without a clipped node, the FNR was 22.2% (95% CI 3.9 to 59.8).
Read carefully before changing practice: every patient still underwent ALND, so this does not establish that omitting dissection is safe, the residual-disease denominator is small (n = 47) making the CI wide, and mapping success was notably poor in inflammatory and other T4 disease. It does support offering SLNB for staging in selected post-NAC cN0 locally advanced patients, with dual tracer and clip confirmation, in surgical counseling. Source: Medscape summary of the JCO publication (October 13, 2026).
FDA Landscape
TumorSight Risk 510(k) clearance (SimBioSys, October 15)
Per a company announcement reported in the week's roundup, FDA granted 510(k) clearance to TumorSight Risk, AI software that combines breast MRI, pathology, and clinical data to generate a 0-to-100 recurrence-risk score (high, intermediate, or low risk) for adult women with HR-positive, HER2-negative stage I to IIIA breast cancer. In a multi-institutional validation of 2,129 patients presented at the 2026 ASCO Annual Meeting, high-risk patients had a 3.3-fold greater recurrence risk. Caveat: I could not access the company's primary release; the figures above are as reported by Physician in the Loop's October 11 to 17 roundup. This is a de novo-class prognostic tool alongside existing genomic assays; watch how it is positioned relative to tissue-based assays before adopting. Source: Physician in the Loop, week of October 11 to 17, 2026.
Dated context: tucatinib maintenance approval landed October 7, just before this window
On October 7, FDA approved tucatinib with trastuzumab and pertuzumab as chemotherapy-free maintenance after induction with trastuzumab, pertuzumab, and a taxane in first-line HER2-positive metastatic disease, based on HER2CLIMB-05 (n = 654): median investigator-assessed PFS 24.9 months (95% CI 21.3 to not reached) versus 16.3 months (95% CI 12.6 to 18.7), HR 0.64 (95% CI 0.51 to 0.80), p < 0.0001, a 35.9% reduction in risk of progression or death. OS was immature. The label carries a boxed warning for hepatotoxicity; serious hepatotoxicity occurred in 3.9% of patients including one fatal drug-induced liver injury. Expect this to reshape first-line HER2+ maintenance conversations now that the labeling details have circulated this week. Sources: FDA approval notice and Pfizer press release (October 7, 2026).
Pending actions
Roche has announced PDUFA goal dates for giredestrant of November 30, 2026 in early-stage breast cancer and December 18, 2026 in advanced disease, following the phase 3 evERA Breast Cancer dataset (giredestrant plus everolimus after CDK4/6i exposure: ITT median PFS 8.8 versus 5.5 months, HR 0.56 [95% CI 0.44 to 0.71], p < 0.001; ESR1-mutant 10.0 versus 5.5 months, HR 0.38 [95% CI 0.27 to 0.54], p < 0.001; OS immature). Source: Roche media release (October 1, 2026). No breast-related ODAC votes or complete response letters surfaced in my searches this week.
Survivorship / Supportive Care
Interdisciplinary survivorship clinic in community practice (JCO Oncology Practice, online October 13)
Stage 0 to IV breast cancer patients treated July 2025 to May 2026 were offered referral to a one-day interdisciplinary survivorship clinic including a survivorship physician, lymphedema therapist, oncology dietitian, and exercise physiologist, with NCCN Distress Thermometer screening and 4 to 8 week follow-up. Of 146 referred, 82 attended and 49 completed follow-up. Median distress fell modestly from 3/10 to 2.5/10; 48 of 49 (98%) rated the clinic as beneficial and all respondents implemented at least one lifestyle or behavioral change. Honest limitations: single institution, small denominator, no control arm, and self-selected attenders, so this is a feasibility and experience signal, not efficacy. It is nonetheless a directly transplantable care model argument for APP-led survivorship program development. Source: JCO Oncology Practice, Volume 22, Number 10_suppl.
Otherwise a quiet week: the exercise/QoL and neuro-behavioral survivorship papers surfacing in my searches (Setouchi project-10, Supportive Care in Cancer fMRI phenotyping) were published October 2 to 3, outside this window, and are held.
Translational / Horizon
Guardrail: nothing in this section is practice-changing today. These are early-stage signals that indicate where the field is heading.
- Early HER2 PET response imaging. In a prospective study of 44 patients with HER2-positive breast cancer published in the October issue of The Journal of Nuclear Medicine, a decrease in tumor uptake of at least 61% on 68Ga-HER2 PET/CT after two neoadjuvant cycles predicted a pCR rate of 85% versus 38% for those with smaller declines. Baseline scans did not discriminate responders. A molecular, target-specific read on early neoadjuvant response; needs prospective interventional validation. Source: EurekAlert release (October 15, 2026).
- When ctDNA misleads at progression. A case series in JCO Precision Oncology (covered October 14) described two patients whose serial ctDNA showed endocrine-resistance alterations (ESR1, PIK3CA, FGFR1) while tissue rebiopsy of progressing liver and bone disease revealed high-grade triple-negative conversion that liquid biopsy could not flag, including receptor status. A useful caution as ctDNA-guided decision-making spreads: ctDNA pools signals across lesions and cannot establish phenotype. Source: The Pathologist summary (October 14, 2026).
- Watch at ESMO (next week). The translational angles most worth tracking in Madrid: SWITCH (4RO), a prospective phase II platform trial testing antigen switching to conserved-payload novel ADCs after prior ADC therapy, which speaks directly to the TOP1-payload resistance literature (acquired TOP1 mutations detected in 12.9% of post-ADC versus 0.7% of ADC-naive patients in circulating DNA series); and TALENT (LBA23), final neoadjuvant T-DXd data in HER2-low, HR-positive early disease. Preview context: OncoDaily ESMO 2026 abstract preview.
Cuts Made: Held for length: the Henlius POHERDY pertuzumab biosimilar head-to-head phase 3 publication in Clinical Cancer Research (October 14), a China-market equivalence dataset with limited US relevance; the pre-window approvals of camizestrant (September 4) and imlunestrant plus abemaciclib (September 18), which your September briefs should have covered; and the evERA Breast Cancer NEJM publication itself (October 1, pre-window, though its biomarker analyses resurface at ESMO). Ask if you want any of these expanded.